Sargramostim to Reverse Myeloid Dendritic Cell Deficiency

Trial Profile

Sargramostim to Reverse Myeloid Dendritic Cell Deficiency

Phase of Trial: Phase II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Sargramostim (Primary)
  • Indications Acute radiation syndrome; Alzheimer's disease; Bone marrow disorders; Chronic lymphocytic leukaemia; Neutropenia; Pneumococcal infections; Prostate cancer; Pulmonary alveolar proteinosis; Stem cell mobilisation
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 Oct 2017 Planned number of patients changed from 15 to 25.
    • 03 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 27 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top